Company profile
OncoPep, Inc.
Privately held: no public share price (Boston/Waltham, MA-based clinical-stage cancer-vaccine biotech (PVX-410, licensed from Dana-Farber), funded via venture rounds (Series D $11M, Dec 2021). No public listing found via WebSearch. Sources: FierceBiotech, BioSpace, PRNewswire. Sources: https://clinicaltrials.gov/study/NCT01718899 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | XBP1, CD138 (Syndecan-1), CS1 (SLAMF7)Peptide | Multiple Myeloma |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.